Most U.S. hedge funds aren't expecting another big stock market sell-off as more firms curb bets on volatility, according to Nomura.Marketsread more
More tit-for-tat tariffs in the U.S.-China trade war could set the global economy up for a recession, according to Morgan Stanley.Marketsread more
A sell-off in chip stocks intensified following a report that chipmakers are cutting ties with Huawei after the Trump administration's ban.Marketsread more
A series of tweets Monday marked the latest chapter in Trump's decadeslong effort to refute published reports that his previous financial problems have rendered him an...Politicsread more
President Trump stands a chance of creating a new economic world order in his China trade fight, says the chief economic advisor of Allianz.Economyread more
Sens. Mitch McConnell and Tim Kaine plan to introduce a bill Monday that would raise the minimum age to buy tobacco to 21 in hopes of curbing what regulators are calling an...Health and Scienceread more
Ford Motor said Monday that it is laying off about 7,000 salaried workers, about 10% of that global workforce, as part of a restructuring plan designed to save the No. 2...Autosread more
Silicon Valley argues that the public market investors focus too much on near-term profits — but investors have embraced money-losing biotech IPOs.Marketsread more
Restaurants are thinking outside the box to attract and retain talent. A report from TDn2K, a restaurant analytics firm, finds that employee vacancies are a major concern for...Restaurantsread more
Forty percent of customers will choose a center to shop at based solely on the food that's there, JLL found in a new study. And nearly 38% of people want healthy options when...Retailread more
Google announced Google Glass Enterprise Edition 2 on Monday, a new set of smart glasses that's catered toward businesses and costs $999. Google has focused on business use...Technologyread more
Federal prosecutors on Friday filed an additional charge in the fraud case against Martin Shkreli, the bad boy ex-pharmaceutical executive.
Prosecutors and defense lawyers said last month that he could be hit with a new count. Asked for comment on Twitter, Shkreli directed CNBC to his lawyer.
In a statement, Shkreli lawyer Ben Brafman said the superseding indictment "adds nothing of value to the government's case that still relies on a flawed theory."
Shkreli was most recently in court May 3. He already was due to return to Brooklyn federal court in the case Monday.
It is not clear if he will be arraigned on the new criminal charge then, or on another day. He is free on a $5 million bond.
A spokeswoman for the U.S. attorney's office in the Eastern District of New York declined to comment.
Shkreli has said he is innocent of the criminal case, in which prosecutors claim he looted his former pharma company Retrophin to pay off investors he was suspected of previously defrauding in a hedge fund he ran. His former lawyer Evan Greebel is a co-defendant in the case.
The new charge is a conspiracy to commit securities fraud count related to unrestricted securities of Retrophin. Prosecutors allege Shkreli and Greebel defrauded potential investors "by concealing Shkreli's beneficial ownership and control of Retrophin's unrestricted or free shares."
It exposes Shkreli to additional prison time.
Greebel's lawyer Reed Brodsky declined to comment.
Shkreli gained notoriety last year after raising the price of a drug used to treat a parasitic disease called toxoplasmosis by more than 5,500 percent as CEO of Turing Pharmaceuticals, the company that he founded after Retrophin's board ousted him. The price of Daraprim jumped to $750 per pill from $13.50 per pill.
Although the price hike drew widespread outrage, it had nothing to do with the criminal charges that were subsequently lodged against him.
In February, investigating drug price increases, citing his Fifth Amendment right against self-incrimination.
Correction: Evan Greebel is a co-defendant in the case. An earlier version misspelled his name.